Genertec Universal Medical Group Company Limited
UMTAF · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.18 | 0.06 | -0.10 |
| FCF Yield | -28.79% | 86.05% | -41.72% | 34.62% |
| EV / EBITDA | 3.39 | -591.87 | 5,749.27 | -362.14 |
| Quality | ||||
| ROIC | 5.16% | 6.27% | 3.58% | 3.35% |
| Gross Margin | 100.00% | 100.65% | 100.00% | 97.33% |
| Cash Conversion Ratio | -1.68 | 8.55 | -2.94 | 4.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.52% | 31.57% | 35.42% | 40.26% |
| Free Cash Flow Growth | -133.18% | 311.32% | -227.58% | 296.17% |
| Safety | ||||
| Net Debt / EBITDA | 2.58 | -499.12 | 4,902.18 | -304.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.10 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 5,115.72 | 0.00 | -1,254.71 |